With briefing documents and history on its side, the biologic license application for NPS Pharmaceuticals Inc.'s Natpara emerged with success from a meeting of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) as expected, scoring eight votes in favor of approval and five against – but a handful of panelists said their ballots might have gone either way.